中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.012 seconds)

    VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF
    2.
    发明申请
    VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF 审中-公开
    各种HCMV PP65，IE1和IE2多核苷酸及其用途

    公开(公告)号：WO2010014567A3

    公开(公告)日：2010-05-27

    申请号：PCT/US2009051895

    申请日：2009-07-28

    Applicant: MERCK SHARP & DOHME ,  FU TONG-MING ,  CASIMIRO DANILO R ,  FREED DANIEL C ,  TANG AIMIN

    Inventor： FU TONG-MING ,  CASIMIRO DANILO R ,  FREED DANIEL C ,  TANG AIMIN

    IPC: C12N15/00 ,  A61K39/12 ,  A61K39/25

    CPC classification number: C07K14/005 ,  C12N2710/16122

    Abstract: The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine.

    Abstract translation: 本发明涉及通过提供编码变体HCMV pp65，IE1和IE2蛋白的多核苷酸及其融合蛋白来引发或增强细胞介导的HCMV感染免疫的组合物和方法。 本发明还提供重组载体，包括但不限于腺病毒和包含所述多核苷酸的质粒载体和包含所述重组载体的宿主细胞。 本文还提供了本文所述的变体HCMV pp65，IE1和IE2蛋白的纯化形式，以及融合蛋白。 变体HCMV蛋白及其融合蛋白可用作用于保护和/或治疗HCMV感染的疫苗。 所述疫苗可用作单一疗法或治疗方案的一部分，所述方案包括施用第二种疫苗，例如多核苷酸，基于细胞的，蛋白质或基于肽的疫苗。

    VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF
    3.
    发明申请
    VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF 审中-公开
    VARIANT HCMV PP65，IE1和IE2多核苷酸及其用途

    公开(公告)号：WO2010014567A2

    公开(公告)日：2010-02-04

    申请号：PCT/US2009/051895

    申请日：2009-07-28

    Applicant: MERCK & CO., INC. ,  FU, Tong-Ming ,  CASIMIRO, Danilo, R. ,  FREED, Daniel, C. ,  TANG, Aimin

    Inventor： FU, Tong-Ming ,  CASIMIRO, Danilo, R. ,  FREED, Daniel, C. ,  TANG, Aimin

    IPC: A61K48/00

    CPC classification number: C07K14/005 ,  C12N2710/16122

    Abstract: The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine.

    Abstract translation: 本发明涉及通过提供编码变体HCMV pp65，IE1和IE2蛋白的多核苷酸及其融合蛋白来引发或增强针对HCMV感染的细胞介导的免疫的组合物和方法。 本发明还提供了重组载体，包括但不限于包含所述多核苷酸的腺病毒和质粒载体以及包含所述重组载体的宿主细胞。 本文还提供了本文所述的变体HCMV pp65，IE1和IE2蛋白的纯化形式以及融合蛋白。 变体HCMV蛋白及其融合蛋白可用作针对HCMV感染的保护和/或治疗的疫苗。 所述疫苗可用作单一疗法或治疗方案的一部分，所述方案包括施用第二种疫苗，例如多核苷酸，基于细胞的，基于蛋白质或基于肽的疫苗。

    CMV NEUTRALIZING ANTIGEN BINDING PROTEINS
    7.
    发明申请
    CMV NEUTRALIZING ANTIGEN BINDING PROTEINS 审中-公开
    CMV中和抗原结合蛋白

    公开(公告)号：WO2017184562A1

    公开(公告)日：2017-10-26

    申请号：PCT/US2017/028062

    申请日：2017-04-18

    Applicant: MERCK SHARP & DOHME CORP. ,  THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  FU, Tong-Ming ,  TANG, Aimin ,  WANG, Dai ,  AN, Zhiqiang ,  ZHANG, Ningyan ,  HA, Sha

    Inventor： FU, Tong-Ming ,  TANG, Aimin ,  WANG, Dai ,  AN, Zhiqiang ,  ZHANG, Ningyan ,  HA, Sha

    IPC: A61K39/00 ,  A61K39/245 ,  A61K39/395 ,  A61K39/42 ,  C12N7/00 ,  C12P21/00

    Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.

    Abstract translation: 本发明涉及抗原结合蛋白，其包括但不限于特异性结合并优选中和人巨细胞病毒（CMV）的单克隆抗体及其抗原结合片段。 本发明的抗原结合蛋白可用作在有此需要的患者中预防和/或治疗CMV感染的预防和/或治疗剂。 本发明还涵盖包含本发明的抗原结合蛋白和药学上可接受的载体的药物组合物。 本发明进一步涉及使用本发明的抗原结合蛋白和药物组合物在有需要的患者中预防或治疗CMV感染的方法。

Patent Agency Ranking